Global Nuclear Medicine Market Report 2013-2017
DUBLIN, December 27, 2013 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/tn88ln/nuclear_medicine) has announced the
addition of the “Global Nuclear Medicine Market Report 2013-2017″
[http://www.researchandmarkets.com/research/tn88ln/nuclear_medicine ] report to their
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes,
comprising of SPECT and PET radioisotopes. The lion’s share of the SPECT market is taken
up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope. Furthermore, the PET
market will witness a double digit growth during the forecast period.
The therapeutic segment contributes only 10% to the global radiopharmaceuticals market
and I-131 has been considered as the gold standard for various oncology treatments in a
combined therapy. Global nuclear medicines market is majorly driven by the increasing
adoption of PET and SPECT scanners, and rising awareness for radiopharmaceuticals, whereas
short half life of isotopes and stringent regulations are the factors that are hindering
the growth of radiopharmaceuticals worldwide.
Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is
witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy
radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease,
Alzheimer’s disease, breast cancer, and bone metastasis will drive the diagnostic
radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and
hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals.
Besides new applications, the potential molecules that are expected to drive the market
include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223
application is still under clinical trial, the market is highly optimistic regarding its
clinical efficiency in prostate cancer, and bone metastasis.
Key Topics Covered: 1 Introduction 1.1 Key Take-Aways 1.2 Report Description 1.3 Markets Covered 1.4 Stakeholders 1.5 Research Methodology 2 Executive Summary 3 Market Overview 3.1 Definition Of Radiopharmaceuticals 3.2 Evolution 3.3 Market Segmentation 3.4 Market Dynamics 3.5 Winning Imperatives 3.6 Burning Issues 3.7 Market Share Analysis 3.8 Value Chain Analysis 3.9 Pipeline Analysis 3.10 Demand & Supply Analysis 3.11 Strategic Benchmarking 3.12 Regulatory Affairs 4 Global Radiopharmaceuticals Market, By Value 4.1 Introduction 4.2 Diagnostic Market 4.3 Therapeutic Market 5 Global Radiopharmaceuticals Market, By Procedural Volume 5.1 Introduction 5.2 Diagnostic Market 5.3 Therapeutic Market 6 Radiopharmaceuticals Market, By Application/Indication 6.1 Introduction 6.2 Diagnostic Market 6.3 Therapeutic Application 7 Enriched Stable Isotopes Market 7.1 Introduction 7.2 Market Overview 7.3 Market Dynamics 7.4 Enriched Stables Market, By Isotopes 7.5 Enriched Stables Market, By Applications 8 Geographic Analysis 8.1 Introduction 8.2 Diagnostic Market 8.3 Therapy Market 8.4 Enriched Stable Isotopes Market 9 Competitive Landscape 9.1 Introduction 9.2 Mergers & Acquisitions 9.3 Agreements, Partnerships, Collaborations & Joint Ventures 9.4 Products Launch 9.5 Expansions 9.6 Other Developments 9.7 Approvals 10 Company Profiles
- Bracco Imaging SPA - Cambridge Isotope Laboratories, Inc - Cardinal Health, Inc - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - Ge Healthcare (Subsidiary Of General Electric Company) - Iba Group - Isotec, Inc (Sigma-Aldrich) - Lantheus Medical Imaging, Inc - Nordion, Inc - Ntp Radioisotopes (PTY), Ltd - Petnet Solutions, Inc (A Subsidiary Of Siemens Medical Solutions Usa, Inc) - Rotem Industries, Ltd, Inc - Taiyo Nippon Sanso Corporation - Urenco Limited
For more information visit
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets